Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, August 14, 2018 ) Global RNAi Drug Delivery Market was worth USD 39.4 billion in 2018 and is expected to reach USD 131.2 billion by 2023 with a CAGR of 27.2 %. RNAi is one of the most important methods of analysing gene functions in eukaryotes. It also plays a pivotal role in the development of therapeutic gene silencing. Gene silencing is a term refers to the ability of a cell to prevent the expression of a specific gene.
RNAi has application in the areas of therapeutics, drug delivery, innovative work and farming. The helpful utilization of RNAi incorporates metabolic activity, cardiology, neurology, oncology, and ophthalmology.
Based on the Geographical Segmentation, the worldwide market is dissected under different regions, in particular, North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa. North America has the largest share in the market followed by Europe because of their high investments. However, Asia-Pacific market is expected to increase at highest CAGR in the following five years because of increasing investments by the major players in this region Major Organisations in the Global RNAi Drug Delivery Market are Tekmira Pharmaceuticals Corp, Alnylam Pharmaceuticals Inc, Merck & Co Inc, Access Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Isis Pharmaceuticals Inc, RXi Pharmaceuticals Corp, Marina Biotech Inc, Calondo Pharmaceuticals Inc, Tacere Therapeutics Inc, Silence Therapeutics plc, Traversa Therapeutics Inc, Quark Pharmaceuticals Inc, PhaseRx Inc, and Sirnaomics Inc.
Browse full research report with TOC on "RNAi Drug Delivery Market, by Drug Delivery (nanoparticle drug delivery technology, pulmonary drug delivery technology, nucleic acid drug delivery technology and aptamer drug delivery technology), by Therapeutic Application (infectious diseases, cardiology, oncology, neurology, ophthalmology and metabolic disorders)"
Market Data Forecast has segmented the Global RNAi Drug Delivery Market on the basis of, Drug Delivery, Therapeutic Application and region: Drug Delivery Outlook (Volume, Kilograms; Revenue, USD Thousands; 2018-2023): Nanoparticle drug delivery technology, pulmonary drug delivery technology, nucleic acid drug delivery technology and aptamer drug delivery technology
Customize Report: https://www.marketdataforecast.com/market-reports/global-rnai-drug-delivery-market-1976/customize-report
Infectious diseases, cardiology, oncology, neurology, ophthalmology and metabolic disorders
Request Sample: https://www.marketdataforecast.com/market-reports/global-rnai-drug-delivery-market-1976/request-sample
Regional Outlook (Volume, Kilograms, Revenue, USD Thousands; 2016-2021): North America, Europe, Asia Pacific, Latin America, Middle East and Africa Further Key Findings from the Report Suggest: • Expanded research in the field of RNA therapeutics has powered the development of worldwide RNAi drug delivery market. • Notwithstanding, high venture cost and stringent controls are a portion of the significant restrictions for the worldwide RNAi drug delivery market. Furthermore, directed delivery of RNA molecules is a key test for the worldwide RNAi drug delivery market. • Numerous organizations occupied with creating RNA therapeutics are confronting troubles in the delivery of RNA atoms to particular tissues to achieve a restorative impact. Expanded research in the field of nanotechnology builds up an open door for the worldwide RNAi drug delivery market. • Expanding mergers and coordinated efforts between life sciences organizations and government inquire about associations is a key pattern for the worldwide RNAi drug delivery market.
Contact Info: Name: Mr. Abhishek Shukla Email: abhishek@marketdataforecast.com Organization: MarketDataForecast™ Phone: +1-888-702-9626 Email: abhishek@marketdataforecast.com
Market Data Forecast.
Abhishek Shukla
+1-888-702-9626
abhishek@marketdataforecast.com
Source: EmailWire.Com
Source: EmailWire.com
|
|
|
|